{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:56:00Z","timestamp":1790488560482,"version":"4.1.0"},"reference-count":120,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.<\/jats:p>","DOI":"10.3390\/cancers11091357","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:56:06Z","timestamp":1568285766000},"page":"1357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Kinase Inhibitors and Ovarian Cancer"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-2768","authenticated-orcid":false,"given":"Periklis","family":"Katopodis","sequence":"first","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"},{"name":"Division of Thoracic Surgery, The Royal Brompton &amp; Harefield NHS Foundation Trust, Harefield Hospital, London UB9 6JH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-0193","authenticated-orcid":false,"given":"Dimple","family":"Chudasama","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-580X","authenticated-orcid":false,"given":"Gurleen","family":"Wander","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Trust, London UB9 6JH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Sales","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Kumar","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manreen","family":"Pandhal","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Anikin","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, The Royal Brompton &amp; Harefield NHS Foundation Trust, Harefield Hospital, London UB9 6JH, UK"},{"name":"Department of Oncology and Reconstructive Surgery, Sechenov First Moscow State Medical University, 119146 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanta","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford GU2 7XH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-5041","authenticated-orcid":false,"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"},{"name":"Mount Vernon Cancer Centre, Rickmansworth Road, Northwood HA6 2RN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Karteris","sequence":"additional","affiliation":[{"name":"Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","unstructured":"Chi, D.S., Berchuck, A., Dizon, D.S., and Yashar, C.M. (2017). Principles and Practice of Gynecologic Oncology, Wolter Kluwer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","article-title":"Epithelial ovarian cancer: An overview","volume":"3","author":"Desai","year":"2014","journal-title":"World J. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-31-14","article-title":"Therapeutic strategies in epithelial ovarian cancer","volume":"31","author":"Kim","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.trecan.2016.12.005","article-title":"Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure","volume":"3","author":"Reinartz","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_8","first-page":"198","article-title":"Management of recurrent epithelial ovarian cancer","volume":"3","year":"2014","journal-title":"Gland Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","article-title":"2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer","volume":"133","author":"Mutch","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Marchetti, C., Palaia, I., De Felice, F., Musella, A., Donfracesco, C., Vertechy, L., Romito, A., Piacenti, I., Musio, D., and Muzii, L. (2015). Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. CANCER Treat. Rev.","DOI":"10.1016\/j.ctrv.2015.10.011"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: Progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nchembio.1212","article-title":"ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system","volume":"9","author":"Polier","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.dld.2013.02.018","article-title":"Field practice studies on sorafenib: Lessons in systemic treatment of hepatocellular carcinoma","volume":"45","author":"Piscaglia","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12057","article-title":"Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET","volume":"78","author":"Marotta","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","first-page":"1519","article-title":"Targeted Treatment of Ovarian Cancer-The Multiple-Kinase-Inhibitor Sorafenib as a Potential Option","volume":"1530","author":"Smolle","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3892\/ol.2017.5557","article-title":"Targeting the Ras\/Raf\/MEK\/ERK pathway in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/107327480701400312","article-title":"Spectrum of activity and mechanism of action of VEGF\/PDGF inhibitors","volume":"14","author":"Homsi","year":"2007","journal-title":"Cancer Control"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjc.6605514","article-title":"Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity","volume":"102","author":"Lee","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1517\/13543784.2013.841138","article-title":"The potential of sunitinib as a therapy in ovarian cancer","volume":"22","author":"Venturini","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1148\/radiol.2017161772","article-title":"In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized (13)C-Pyruvate MR Spectroscopy and (18)F-FDG PET\/CT Imaging in a Mouse Model","volume":"285","author":"Ravoori","year":"2017","journal-title":"Radiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2017.05.013","article-title":"Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer-Results of the PACOVAR-trial","volume":"146","author":"Dinkic","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer","volume":"32","author":"Floquet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","article-title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance th","volume":"29","author":"Friedlander","year":"2018","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/OTT.S78805","article-title":"Profile of nintedanib in the treatment of solid tumors: The evidence to date","volume":"8","author":"Awasthi","year":"2015","journal-title":"OncoTargets. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Secord, A.A., McCollum, M., Davidson, B.A., Broadwater, G., Squatrito, R., Havrilesky, L.J., Gabel, A.C., Starr, M.D., Brady, J.C., and Nixon, A.B. (2019). Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecol. Oncol.","DOI":"10.1016\/j.ygyno.2019.03.246"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2017.1383384","article-title":"The role of Cediranib in ovarian cancer","volume":"18","author":"Orbegoso","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_40","first-page":"636","article-title":"Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors","volume":"13","author":"Normanno","year":"2010","journal-title":"IDrugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45954","DOI":"10.1038\/srep45954","article-title":"Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells","volume":"7","author":"Momeny","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/1078-0432.CCR-11-0411","article-title":"Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor -1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors","volume":"17","author":"Eskens","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2019.37.15_suppl.5538","article-title":"Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"37","author":"Swetzig","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2174\/1389450118666170329095807","article-title":"Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors","volume":"18","author":"Duan","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00404-007-0333-5","article-title":"HPV induced ovarian squamous cell carcinoma: Case report and review of the literature","volume":"276","author":"Verguts","year":"2007","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study","volume":"32","author":"Vergote","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2017.01.031","article-title":"The development and use of vascular targeted therapy in ovarian cancer","volume":"145","author":"Chase","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1158\/1078-0432.CCR-10-0527","article-title":"\u201cContextual\u201d synthetic lethality and\/or loss of heterozygosity: Tumor hypoxia and modification of DNA repair","volume":"16","author":"Chan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1073\/pnas.0904783107","article-title":"Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130","volume":"107","author":"Hegan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Washington, C.R., Richardson, D.L., and Moore, K.N. (2019). Olaparib in the treatment of ovarian cancer. Future Oncol.","DOI":"10.2217\/fon-2019-0271"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","article-title":"Cancer stem cells: Impact, heterogeneity, and uncertainty","volume":"21","author":"Magee","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-17-3697","article-title":"Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells","volume":"24","author":"Simpkins","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","article-title":"A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer","volume":"109","author":"Posadas","year":"2007","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11523-015-0369-6","article-title":"Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy","volume":"10","author":"Despierre","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2010.05.005","article-title":"A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)","volume":"118","author":"Hirte","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2010.08.008","article-title":"Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment","volume":"119","author":"Blank","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2011.10.022","article-title":"A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study","volume":"124","author":"Garcia","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2011.03.030","article-title":"Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory\/resistant ovarian and primary peritoneal carcinoma","volume":"122","author":"Weroha","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_67","first-page":"1483","article-title":"Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: A phase 2 trial","volume":"22","author":"Lheureux","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: Targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ntanasis-stathopoulos, I., Fotopoulos, G., and Kotteas, E.A. (2016). The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review. Cancer Investig., 7907.","DOI":"10.1080\/07357907.2016.1206117"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","article-title":"Activity of the multikinase inhibitor dasatinib against ovarian cancer cells","volume":"101","author":"Konecny","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2004","journal-title":"Cancer Metastasis Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","first-page":"735","article-title":"Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity","volume":"14","author":"Muthuswamy","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_74","first-page":"2027","article-title":"Fibroblast growth factor receptor-1 regulation of Src family kinases","volume":"10","author":"Landgren","year":"1995","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/sj.onc.1201496","article-title":"Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential","volume":"15","author":"Mao","year":"1997","journal-title":"Oncogene"},{"key":"ref_76","first-page":"171","article-title":"Activity of pp60c-src in 60 different cell lines derived from human tumors","volume":"14","author":"Budde","year":"1994","journal-title":"Cancer Biochem. Biophys."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2006.06.3743","article-title":"An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer","volume":"25","author":"Dressman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-010-1024-7","article-title":"Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo","volume":"128","author":"Chen","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerdagger","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Andorfer, P., Heuwieser, A., Heinzel, A., Lukas, A., Mayer, B., and Perco, P. (2016). Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Syst. Biol., 10.","DOI":"10.1186\/s12918-016-0278-z"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: Therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clinthera.2018.01.012","article-title":"Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions","volume":"40","author":"Vetter","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer","volume":"137","author":"Mabuchi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref_90","first-page":"47","article-title":"Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry","volume":"43","author":"Kumar","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737140.2014.864562","article-title":"Temsirolimus for advanced renal cell carcinoma","volume":"14","author":"Bergmann","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: Efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pediatrneurol.2017.04.008","article-title":"Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus","volume":"72","author":"Arroyo","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization","volume":"28","author":"Sehgal","year":"1975","journal-title":"J. Antibiot."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1073\/pnas.92.11.4947","article-title":"Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue","volume":"92","author":"Chen","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","first-page":"4809751","article-title":"A Review of mTOR Pathway Inhibitors in Gynecologic Cancer","volume":"2017","author":"Paulino","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.18632\/oncotarget.1834","article-title":"Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus","volume":"5","author":"Wheler","year":"2014","journal-title":"Oncotarget"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00280-012-1889-8","article-title":"A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors","volume":"70","author":"Vlahovic","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2010.02.022","article-title":"A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and\/or recurrent gynecologic malignancies","volume":"117","author":"Temkin","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s13277-015-3922-0","article-title":"The anti-ovarian cancer activity by WYE-132, a mTORC1\/2 dual inhibitor","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1200\/JCO.2016.34.15_suppl.5552","article-title":"Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer","volume":"34","author":"Taylor","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1055\/s-0043-118907","article-title":"PI3K\/AKT\/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?","volume":"77","author":"Gasparri","year":"2017","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-17-3060","article-title":"Integrative Kinome Profiling Identifies mTORC1\/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma","volume":"24","author":"Caumanns","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","article-title":"AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules","volume":"14","author":"Guichard","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"113874","DOI":"10.18632\/oncotarget.23022","article-title":"Evaluation of the combination of the dual m-TORC1\/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models","volume":"8","author":"Thavasu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","article-title":"Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","volume":"29","author":"Basu","year":"2018","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"ref_110","first-page":"3529","article-title":"Differential expression of mTOR signalling components in drug resistance in ovarian cancer","volume":"30","author":"Foster","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0303-7207(03)00068-6","article-title":"Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; An exception to the rule","volume":"202","author":"Sundfeldt","year":"2003","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3892\/ijo.2016.3531","article-title":"Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro","volume":"49","author":"Chudasama","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ediriweera, M.K., Tennekoon, K.H., and Samarakoon, S.R. (2019). Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin. Cancer Biol.","DOI":"10.1016\/j.semcancer.2019.05.012"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Liu, M., Clarke, C.J., Salama, M.F., Choi, Y.J., Obeid, L.M., and Hannun, Y.A. (2017). Co-ordinated activation of classical and novel PKC isoforms is required for PMA-induced mTORC1 activation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184818"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14737140.2015.1003810","article-title":"Targeting protein kinase C subtypes in pancreatic cancer","volume":"15","author":"Storz","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3109\/10428194.2013.861066","article-title":"A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma","volume":"55","author":"Jourdan","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2011.02.013","article-title":"A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies","volume":"121","author":"Usha","year":"2011","journal-title":"Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:19:42Z","timestamp":1760188782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":120,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cancers11091357"],"URL":"https:\/\/doi.org\/10.3390\/cancers11091357","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}